Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297111 | 1.00 | MAPT (0.46) | MAPTLMNAMAPK1NPSR1MEN1 | |
| SCHEMBL933767 | 0.87 | MAPT (0.51) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL933766 | 0.87 | MAPT (0.51) | MAPTLMNANPSR1MEN1KMT2A | |
| SCHEMBL19321725 | 0.84 | GPR52 (0.55) | MAPTLMNAMAPK1NPSR1MEN1 | |
| SCHEMBL17592718 | 0.83 | KDM4E (0.43) | LMNAMEN1KMT2ATGM2HTT | |
| SCHEMBL17592772 | 0.83 | KDM4E (0.43) | LMNAMEN1KMT2ATGM2HTT | |
| SCHEMBL17592719 | 0.83 | KDM4E (0.43) | LMNAMEN1KMT2ATGM2HTT | |
| SCHEMBL6263498 | 0.83 | MAPT (0.57) | MAPTLMNAF13A1TGM2TGM1 | |
| SCHEMBL6263496 | 0.83 | MAPT (0.57) | MAPTLMNAF13A1TGM2TGM1 | |
| SCHEMBL23188844 | 0.83 | LMNA (0.50) | MAPTLMNAMAPK1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-3954684-A1 | PROCESS FOR THE PREPARATION OF HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | Ardelyx, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3504205-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3504205-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | Ardelyx, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-5648503-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | ALLERGAN (US) | 1997-07-15 | — | — | US | disclosed |
| US-5618943-A | SKIN DISORDERS, ANTIINFLAMMATORY AGENTS | ALLERGAN | 1997-04-08 | — | — | US | disclosed |
| US-5618931-A | SKIN DISORDERS, ANTIINFLAMMATORY AGENTS | ALLERGAN | 1997-04-08 | — | — | US | disclosed |
| US-5605915-A | TREATING SKIN DISORDERS | ALLERGAN | 1997-02-25 | — | — | US | disclosed |
| US-5599967-A | SKIN DISORDERS, VISION DISORDERS, ANTIINFLAMMATORY AGENTS | ALLERGAN | 1997-02-04 | — | — | US | disclosed |
| US-5591858-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | ALLERGAN | 1997-01-07 | — | — | US | disclosed |
| US-5543534-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN | 1996-08-06 | — | — | US | disclosed |
| WO-1996020930-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5514825-A | SYNTHETIC RETINOIDS | ALLERGAN, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5489584-A | ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS; TREATING SKIN DISORDER, CARDIOVASCULAR DISORDER | ALLERGAN, INC. (US) | 1996-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | MAPT 4700/4885LMNA 4357/4885MAPK1 1736/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | MAPT 4700/4885LMNA 4357/4885MAPK1 1736/4885 |
| US-10793568-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | MAPT 4713/4885LMNA 4360/4885MAPK1 1894/4885 |
| US-20190233420-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | MAPT 4713/4885LMNA 4360/4885MAPK1 1894/4885 |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | MAPT 4700/4885LMNA 4357/4885MAPK1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.